Cargando…

Efficacy and safety of a mobile app intervention in patients with inflammatory arthritis: a prospective pilot study

EULAR highlighted the essential role of digital health in increasing self-management and improving clinical outcomes in patients with arthritis. The objective of this study was to evaluate the efficacy and safety of the digital health application (DHA) in patients with inflammatory arthritis. We ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Fedkov, Dmytro, Berghofen, Andrea, Weiss, Christel, Peine, Christine, Lang, Felix, Knitza, Johannes, Kuhn, Sebastian, Krämer, Bernhard K., Leipe, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483251/
https://www.ncbi.nlm.nih.gov/pubmed/36112186
http://dx.doi.org/10.1007/s00296-022-05175-4
_version_ 1784791632557637632
author Fedkov, Dmytro
Berghofen, Andrea
Weiss, Christel
Peine, Christine
Lang, Felix
Knitza, Johannes
Kuhn, Sebastian
Krämer, Bernhard K.
Leipe, Jan
author_facet Fedkov, Dmytro
Berghofen, Andrea
Weiss, Christel
Peine, Christine
Lang, Felix
Knitza, Johannes
Kuhn, Sebastian
Krämer, Bernhard K.
Leipe, Jan
author_sort Fedkov, Dmytro
collection PubMed
description EULAR highlighted the essential role of digital health in increasing self-management and improving clinical outcomes in patients with arthritis. The objective of this study was to evaluate the efficacy and safety of the digital health application (DHA) in patients with inflammatory arthritis. We assessed demographic parameters, treatment regimen, disease activity, and other patient-reported outcomes at baseline and after 4 weeks of DHA use added to standard care treatment. Of 17 patients, who completed the study, 7 (41.2%) patients were male, ranging from 19 to 63 (40.5 ± 12.2) years. No significant change in antirheumatic treatment was observed during the study. Statistically significant improvements (p < 0.05) were noted for health-related quality of life (increase in Physical Component Summary of Short Form-36 (SF-36) by 23.6%) and disease activity (decrease of Clinical Disease Activity Index and Simple Disease Activity Index by 38.4% and 39.9%, respectively). Clinically significant improvement was demonstrated for SF-36 Total Score (+ 14.4%), disease activity (Rheumatoid Arthritis Disease Activity Index− 5 to 15.9%), and depression (Patient Health Questionnaire− 9 to 13.5%). None of the efficacy parameters showed negative trends. No adverse events were reported throughout the study. The usability level was high i.e., the mean mHealth Application Usability Questionnaire Score of 5.96 (max.: 7.0) demonstrated a high level of application usability. This suggests that using a personalized disease management program based on DHA significantly improves several measures of patient-reported outcomes and disease activity in patients with inflammatory arthritis in a timely manner. These findings highlight the potential of complementary digital therapy in patients with inflammatory arthritis.
format Online
Article
Text
id pubmed-9483251
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-94832512022-09-19 Efficacy and safety of a mobile app intervention in patients with inflammatory arthritis: a prospective pilot study Fedkov, Dmytro Berghofen, Andrea Weiss, Christel Peine, Christine Lang, Felix Knitza, Johannes Kuhn, Sebastian Krämer, Bernhard K. Leipe, Jan Rheumatol Int Observational Research EULAR highlighted the essential role of digital health in increasing self-management and improving clinical outcomes in patients with arthritis. The objective of this study was to evaluate the efficacy and safety of the digital health application (DHA) in patients with inflammatory arthritis. We assessed demographic parameters, treatment regimen, disease activity, and other patient-reported outcomes at baseline and after 4 weeks of DHA use added to standard care treatment. Of 17 patients, who completed the study, 7 (41.2%) patients were male, ranging from 19 to 63 (40.5 ± 12.2) years. No significant change in antirheumatic treatment was observed during the study. Statistically significant improvements (p < 0.05) were noted for health-related quality of life (increase in Physical Component Summary of Short Form-36 (SF-36) by 23.6%) and disease activity (decrease of Clinical Disease Activity Index and Simple Disease Activity Index by 38.4% and 39.9%, respectively). Clinically significant improvement was demonstrated for SF-36 Total Score (+ 14.4%), disease activity (Rheumatoid Arthritis Disease Activity Index− 5 to 15.9%), and depression (Patient Health Questionnaire− 9 to 13.5%). None of the efficacy parameters showed negative trends. No adverse events were reported throughout the study. The usability level was high i.e., the mean mHealth Application Usability Questionnaire Score of 5.96 (max.: 7.0) demonstrated a high level of application usability. This suggests that using a personalized disease management program based on DHA significantly improves several measures of patient-reported outcomes and disease activity in patients with inflammatory arthritis in a timely manner. These findings highlight the potential of complementary digital therapy in patients with inflammatory arthritis. Springer Berlin Heidelberg 2022-09-16 2022 /pmc/articles/PMC9483251/ /pubmed/36112186 http://dx.doi.org/10.1007/s00296-022-05175-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Observational Research
Fedkov, Dmytro
Berghofen, Andrea
Weiss, Christel
Peine, Christine
Lang, Felix
Knitza, Johannes
Kuhn, Sebastian
Krämer, Bernhard K.
Leipe, Jan
Efficacy and safety of a mobile app intervention in patients with inflammatory arthritis: a prospective pilot study
title Efficacy and safety of a mobile app intervention in patients with inflammatory arthritis: a prospective pilot study
title_full Efficacy and safety of a mobile app intervention in patients with inflammatory arthritis: a prospective pilot study
title_fullStr Efficacy and safety of a mobile app intervention in patients with inflammatory arthritis: a prospective pilot study
title_full_unstemmed Efficacy and safety of a mobile app intervention in patients with inflammatory arthritis: a prospective pilot study
title_short Efficacy and safety of a mobile app intervention in patients with inflammatory arthritis: a prospective pilot study
title_sort efficacy and safety of a mobile app intervention in patients with inflammatory arthritis: a prospective pilot study
topic Observational Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483251/
https://www.ncbi.nlm.nih.gov/pubmed/36112186
http://dx.doi.org/10.1007/s00296-022-05175-4
work_keys_str_mv AT fedkovdmytro efficacyandsafetyofamobileappinterventioninpatientswithinflammatoryarthritisaprospectivepilotstudy
AT berghofenandrea efficacyandsafetyofamobileappinterventioninpatientswithinflammatoryarthritisaprospectivepilotstudy
AT weisschristel efficacyandsafetyofamobileappinterventioninpatientswithinflammatoryarthritisaprospectivepilotstudy
AT peinechristine efficacyandsafetyofamobileappinterventioninpatientswithinflammatoryarthritisaprospectivepilotstudy
AT langfelix efficacyandsafetyofamobileappinterventioninpatientswithinflammatoryarthritisaprospectivepilotstudy
AT knitzajohannes efficacyandsafetyofamobileappinterventioninpatientswithinflammatoryarthritisaprospectivepilotstudy
AT kuhnsebastian efficacyandsafetyofamobileappinterventioninpatientswithinflammatoryarthritisaprospectivepilotstudy
AT kramerbernhardk efficacyandsafetyofamobileappinterventioninpatientswithinflammatoryarthritisaprospectivepilotstudy
AT leipejan efficacyandsafetyofamobileappinterventioninpatientswithinflammatoryarthritisaprospectivepilotstudy